ERS Genomics and medicines discovery catapult sign CRISPR/Cas9 license agreement

Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug discovery innovation center, have signed a non-exclusive commercial-use CRISPR license agreement.

Racism in obstetric care linked to higher blood pressure in mothers

Mothers of color who faced racism or microaggressions during obstetric care had higher blood pressure after delivering their babies compared to people of color who

January 15, 2025

Checking the facts on Medicaid use by Latinos

Spending cuts, immigration, and Medicaid are at the top of the Washington agenda. That climate provides fertile ground for misinformation and myths to multiply on

March 17, 2025

Metformin linked to lower mortality in ICU patients with diabetes and heart failure

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Patients receiving intensive care often have diabetes mellitus (DM) together with chronic heart failure

June 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.